1. Epigenetics
  2. Epigenetic Reader Domain

(+)-JQ-1 (Synonyms: JQ1)

Cat. No.: HY-13030 Purity: 99.90%
Handling Instructions

(+)-JQ-1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for the first and second bromodomain (BRD4(1/2)).

For research use only. We do not sell to patients.
(+)-JQ-1 Chemical Structure

(+)-JQ-1 Chemical Structure

CAS No. : 1268524-70-4

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 92 In-stock
5 mg USD 84 In-stock
10 mg USD 108 In-stock
50 mg USD 288 In-stock
100 mg USD 480 In-stock
200 mg USD 840 In-stock
500 mg USD 1800 In-stock
1 g USD 2160 In-stock
5 g USD 6000 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of (+)-JQ-1:

    (+)-JQ-1 purchased from MCE. Usage Cited in: Cancer Lett. 2018 Apr 28;420:195-207.

    Shh-Light 2 cells are transfected with Gli1 or Gli2 plasmids and the expression of proteins are analyzed by Western blot. Positive control JQ1, CBC and CBD inhibit Gli1 and Gli2 overexpression induced Gli luciferase activity, GDC-0499 and GANT61 have no effects.

    (+)-JQ-1 purchased from MCE. Usage Cited in: Mol Cancer Ther. 2016 Jun;15(6):1217-26.

    JQ1-mediated c-MYC repression correlates with growth inhibition. BETi preferentially inhibit c-MYC protein expression in sensitive cell lines. JQ1-sensitive GP5D, HT29 and LIM1215 cells and JQ1-resistant KM12, SW480 and HuTu80 cells where treated with JQ1 (500 nM) for 2-24 hours and c-MYC protein expression determined by western blot.

    (+)-JQ-1 purchased from MCE. Usage Cited in: J Biol Chem. 2016 Nov 4;291(45):23756-23768.

    BET inhibition blocks growth of TNBC cells without consistently downregulating MYC. Western blot analysis of MYC expression levels in TNBC cell lines treated for 24 hours with vehicle or 500 nM JQ1. Values on the western blot are relative to the vehicle-treated 1143 sample following normalization to β-actin.

    (+)-JQ-1 purchased from MCE. Usage Cited in: Biochim Biophys Acta. 2016 Dec;1859(12):1527-1537.

    RVX208 increases CTGF and CYR61 expression and TAZ protein level in HCT116 cells.

    (+)-JQ-1 purchased from MCE. Usage Cited in: Biochim Biophys Acta. 2016 Dec;1859(12):1527-1537.

    JQ1 treatment decreases β-catenin levels in HCT116 cells, but increases TAZ protein. When cells reach confluence, they are serum-starved overnight and pretreated with DMSO or JQ1 (500 nM) for 1 hour, followed by growth medium (containing 10% serum) stimulation for 24 hours.

    (+)-JQ-1 purchased from MCE. Usage Cited in: PLoS Pathog. 2016 Oct 20;12(10):e1005950.

    Dose effect of JQ1 on HSV infection. Vero cells are treated with JQ1 at concentrations as indicated. HSV-1 or HSV-2 at 1 MOI are used. The samples are used for protein expression analysis by western blot.

    (+)-JQ-1 purchased from MCE. Usage Cited in: Metabolism. 2016 Oct;65(10):1478-88.

    The BRD4 protein level in the liver is significantly suppressed by force-feeding fructose or glucose with (+)-JQ1. Protein levels of Brd4 in the liver of mice force-fed with glucose or fructose, with or without (+)-JQ1. Quantification of protein levels is performed by normalization against the level of β-actin (n = 6).

    (+)-JQ-1 purchased from MCE. Usage Cited in: J Med Chem. 2017 Jun 22.

    Protein degradation profile of VHL-based BET degraders. Sub-confluent HeLa cells are treated for 24 h with varying concentration of test compounds JQ1(Compound 3), I-BET726 (Compound 4). Protein extracts are separated by SDS-PAGE and then analyzed by Western blot. Proteins Brd4, Brd3, Brd2 and β-actin are probed for JQ1and I-BET726 with specific antibodies.

    (+)-JQ-1 purchased from MCE. Usage Cited in: Genome Res. 2017 Nov;27(11):1830-1842.

    Ki67 immunohistochemistry and H&E stained sections from representative xenograft per treatment arm. A marked decrease in the proliferation marker Ki67 is observed in xenografts treated with JQ1.

    (+)-JQ-1 purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Jan 26;9(2):129.

    The effects of treatment with the indicated epigenetic inhibitors on cleaved PARP (Clv-PARP) expression in both PC9/ER and HCC827/ER cells. β-actin is used as a loading control.

    (+)-JQ-1 purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Jan 26;9(2):129.

    H3K9Me2, PTEN, p-AKT, and AKT expression levels are measured in PC9/ER xenograft tumor tissues. β-actin is used as a loading control.

    (+)-JQ-1 purchased from MCE. Usage Cited in: Cancer Biol Ther. 2018 Jan 15:1-9.

    NSCLC cells are treated with 0-8 μM JQ1 for 24h, then the whole-cell lysates are prepared and subjected to western blot assay.

    (+)-JQ-1 purchased from MCE. Usage Cited in: Cancer Lett. 2018 Apr 10;419:64-74.

    ESCC cell lines are treated with 500 nM JQ1 for 48 h, whole cell lysates are analyzed by western blotting. The expressions of p21 and p27 are further upregulated by JQ1 concomitant with cell cycle arrest at G1 phase.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    (+)-JQ-1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for the first and second bromodomain (BRD4(1/2)).

    IC50 & Target

    IC50: 77/33 nM (BRD4(1/2))[1]

    In Vitro

    (+)-JQ1 represents a potent, highly specific and Kac competitive inhibitor for the BET family of bromodomains. (+)-JQ1 (100 nM, 48 h) prompts squamous differentiation exhibited by cell spindling, flattening and increased expression of keratin. (+)-JQ1 (250 nM) induces rapid expression of keratin in treated NMC 797 cells compared to (-)-JQ1 (250 nM) and vehicle controls, as determined by quantitative immunohistochemistry.(+)-JQ1 (250 nM) elicits a time-dependent induction of strong (3+) keratin staining of treated NMC 797 cells, compared to (-)-JQ1 (250 nM)[1]. (+)-JQ1 is a potent thienodiazepine inhibitor (Kd=90 nM) of the BET family coactivator protein BRD4, which is implicated in the pathogenesis of cancer via transcriptional control of the MYC oncogene. Dose-ranging studies of (+)-JQ1 demonstrates potent inhibition of H4Kac4 binding with a IC50 value of 10 nM for murine BRDT(1) and 11 nM for human BRDT(1)[2].

    In Vivo

    Pharmacokinetic studies of (+)-JQ1 are performed in CD1 mice following intravenous and oral administration. Mean plasma concentration-time profiles of (+)-JQ1 after intravenous dosing (5 mg/kg). The pharmacokinetic parameters for intravenous (+)-JQ1 demonstrate excellent drug exposure (AUC=2090 hr*ng/mL) and an approximately one hour half-life (T1/2). Mean plasma concentration-time profiles of (+)-JQ1 after oral dosing (10 mg/kg). The pharmacokinetic parameters for oral (+)-JQ1 demonstrate excellent oral bioavailability (F=49%), peak plasma concentration (Cmax=1180 ng/mL) and drug exposure (AUC=2090 hr*ng/mL)[1].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.1882 mL 10.9412 mL 21.8823 mL
    5 mM 0.4376 mL 2.1882 mL 4.3765 mL
    10 mM 0.2188 mL 1.0941 mL 2.1882 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay

    (+)-JQ1 is dissolved in DMSO and stored, and then diluted with appropriate media (DMSO 0.025%) before use[1].

    NUT midline carcinoma patient cell lines (797 and 11060) are plated in T-25 flasks and grown in DMEM (797) or RPMI (11060) containing 10 % fetal bovine serum and 1 % Penicillin/Streptomycin. Cells are treated with either 250 nM (+)-JQ1, 250 nM (-)-JQ1 or the equivalent volume of DMSO (0.025%). At the desired time point, 2×106 cells are spun at 500× g for 5 minutes at 4°C and washed with PBS. Pellets are resuspended in 1 mL of cold PBS and added dropwise while gently vortexing to 9 mL 70 % ethanol in a 15 mL polypropylene centrifuge tube. Fixed cells are then frozen at -20°C overnight. The next day, cells are centrifuged at 500× g for 10 minutes at 4°C and washed with 3 mL of cold PBS. Cells are resuspended in 500 μL of propidium iodide staining solution (0.2 mg/mL RNAse A, 0.02 mg/mL propidium iodide, 0.1 % Triton-X in PBS) and incubated for 20 minutes at 37°C. Samples are then transferred to ice and analyzed on a BD FACS Canto II. Histograms are generated and cell cycle analysis is performed using FlowJo flow cytometry analysis software[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    (+)-JQ1 is formulated for intravenous injection in 10 % DMSO and 10 % HP-β-CD (Mice)[1].
    (+)-JQ1 is formulated in saline, 10% 2-Hydroxypropyl-β-cyclodextrin and 10% DMSO (Rats)[2].

    Male CD1 mice (24-29 g) are treated with a single dose of (+)-JQ1 at 5 mg/kg for intravenous tail vein injection studies and 10 mg/kg for oral gavage studies. Approximately 150 μL of blood are taken from animals by retro-orbital puncture under anesthesia with Isoflurane into EDTA tubes at pre-specified time intervals: 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 5, 8 and 24 hours. Three animals are analyzed per time point. Blood samples are put on ice and centrifuged to obtain plasma samples (2000× g, 5 min under 4°C) within 15 minutes post-sampling. Plasma samples are stored at approximately -70°C until analysis is performed. Mice are provided free access to food and water throughout the study.
    Adult male Sprague-Dawley rats are treated with vehicle or (+)-JQ1(10 mg/kg). Treatment is administered IP at 1/100 body mass. Rats are checked twice-daily for mortality and weighed on days 1, 3, 7, 14, and 21. The treatment regimen utilized 4 days of 50 mg/kg JQ1 administered daily which is decreased to 10 mg/kg twice daily for the remainder of the study due to the appearance of adverse effects in a subset of animals. For all animals completing 3 weeks of treatment, testis mass, sperm motility, and sperm counts are determined as described for mouse studies. In brief, testes are fixed in Bouin’s and prepared for histology. The other half is minced in warm M16 buffer and used for sperm counts and motility studies. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.



    O=C(C[[email protected]]1C2=NN=C(N2C3=C(C(C4=CC=C(C=C4)Cl)=N1)C(C)=C(S3)C)C)OC(C)(C)C

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 45 mg/mL

    (+)-JQ-1 (JQ1) is formulated in 10% DMSO and 90% of a 10% 2-hydroxypropyl-β-cyclodextrin solution[3].
    (+)-JQ-1 (JQ1) is prepared in vehicle (20% hydroxypropyl-β-cyclodextrin, 5% DMSO, 0.2% Tween-80 in saline)[4].
    (+)-JQ-1 (JQ1) is prepared in vehicle (1:1 propylene glycol:water)[5].
    (+)-JQ-1 (JQ1) is prepared in vehicle (5% DMSO in 10% 2-hydroxypropyl-ß-cyclodextrin solution)[6].
    (+)-JQ-1 is prepared in vehicle (10% hydroxypropyl β-cyclodextrin in water)[7].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.


    Purity: 99.90%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.: